NCT01843855View on ClinicalTrials.gov

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

September 30, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Exendin 9,39

Exendin 9,39 is a competitive antagonist of endogenous GLP-1.

DRUG

Placebo

A saline infusion will be given to match the study drug infusion.

Trial Locations (1)

55905-0001

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Adrian Vella

OTHER

NCT01843855 - The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass | Biotech Hunter | Biotech Hunter